DGAP-News: MC2 Therapeutics / Key word(s): Agreement/Market launch
MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for
European Rights to Wynzora(R) Cream for treatment of Plaque Psoriasis
2021-02-17 / 09:00
The issuer is solely responsible for the content of this announcement.
Almirall and MC2 Therapeutics Enter a License, Collaboration and Commercialization Agreement for European Rights to
Wynzora(R) Cream for Treatment of Plaque Psoriasis
In this collaboration Almirall will commercialize Wynzora(R) Cream for treatment of plaque psoriasis in Europe and MC2
Therapeutics will be responsible for manufacturing and supply.
- MC2 Therapeutics and Almirall partner to make Wynzora(R) Cream a leading topical product for Plaque Psoriasis in
- In a large European based Phase 3 clinical trial (n=490), Wynzora(R) Cream has demonstrated substantial efficacy with
a PGA treatment success of 51% and beneficial treatment convenience (1)
- Marketing Authorization Application (MAA) in Europe of Wynzora(R) Cream has been filed and approval is expected this
BARCELONA, Spain and COPENHAGEN, Denmark, February 17, 2021 -- Almirall S.A. (BME: ALM), a global biopharmaceutical
company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical
therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics
has granted Almirall exclusive European rights to commercialize Wynzora(R) Cream for treatment of plaque psoriasis. In
exchange, MC2 Therapeutics is eligible to receive upfront to launch payments of EUR 15 million in addition to
significant sales milestone payments and double-digit royalties on the European sales of Wynzora(R) Cream. Almirall and
MC2 Therapeutics partner to make Wynzora(R) Cream a leading topical product for treatment of plaque psoriasis in Europe
- a market, which currently is more than 25 million units in sales volume annually (2). The market represents a
significant opportunity for Wynzora(R) Cream as the calcipotriene and betamethasone dipropionate segment accounts for
approximately 35% of share of volume and annual sales of more than USD300 million (2).
Wynzora(R) Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) received US FDA approval on 20th
July 2020. Wynzora(R) Cream is currently under review in Europe supported by two Phase 3 trials (1), including an EU
head-to-head trial against active comparator Dovobet/Daivobet(R) Gel. The Physician Global Assessment (PGA) treatment
success defined as a minimum two-point decrease in the PGA score to clear or almost clear disease at Week 8 was 51% for
Wynzora(R) Cream vs. 6% for vehicle (p<0.0001). The treatment satisfaction score using the Psoriasis Treatment
Convenience Scale (PTCS) was superior compared to Dovobet/Daivobet(R) Gel. Using MC2 Therapeutics' PAD(TM) Technology,
Wynzora(R) Cream was uniquely designed to provide patients a new treatment option in their daily routines by combining
the three essentials of a topical therapy in one single product namely high efficacy, a favorable safety profile and
convenience of use.
Mike Mcclellan, Chief Financial Officer (CFO) and interim Chief Executive Officer (CEO) said: "We are thrilled with
this agreement with MC2 Therapeutics. Wynzora(R) Cream has demonstrated significant improvements in the skin clearance
of psoriasis patients. It is the perfect addition to our growing psoriasis portfolio, which includes multiple treatment
options, covering the whole spectrum of the disease. We are delighted that soon we will be able to offer this novel
topical treatment to European dermatologists and their patients."
Jesper J. Lange, CEO of MC2 Therapeutics, commented: "We are excited to partner with Almirall, an established company
with deep expertise in dermatology and psoriasis and with the focus to improve patients' needs. Bringing together
Almirall's excellence in commercial operations and MC2 Therapeutics' commitment to ensure a global roll-out of Wynzora
(R) Cream we will, upon approval, ensure a strong launch of Wynzora(R) Cream for the benefit of the many patients
living with plaque psoriasis and for the healthcare practitioners who provide care. We believe that the unique
combination of compelling clinical efficacy, a favorable safety profile and treatment convenience are key components to
treatment adherence and overall better patient satisfaction in topical treatment of plaque psoriasis in a real-world
About Plaque Psoriasis
Psoriasis is a common, non-contagious, chronic skin disease, with no clear cause or cure. The negative impact of plaque
psoriasis on people's lives can be immense as it affects the appearance of the skin with red, scaly plaques. Psoriasis
affects people of all ages, and in all countries. The reported prevalence of psoriasis in Europe varies from 0.6% to
6.5% with an average of approximately 3% of the population (3,4), making psoriasis a serious global problem with more
than 100 million individuals affected worldwide (5). The flares of psoriasis can be unpredictable and significant
comorbidities are common, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease
and depression (4).
About Wynzora(R) Cream
Wynzora(R) Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) is under review in Europe as a
topical treatment of plaque psoriasis in adults. Wynzora^(R) Cream is based on PAD(TM) Technology, enabling an aqueous
cream formulation of both calcipotriol and betamethasone as dipropionate and optimal delivery of active ingredients
into the target tissue. Wynzora^(R) Cream was approved in the US by the FDA on 20^th July 2020.
Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare
professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of
our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest
in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in
The company, founded in 1943 and headquartered in Barcelona, is public traded on the Spanish Stock Exchange and is a
member of the IBEX 35 (BME: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of
patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13
subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.
For additional information on Almirall, please visit www.almirall.com
About MC2 Therapeutics
MC2 Therapeutics is a privately held commercial stage pharmaceutical company committed to build leadership in topicals
for autoimmune and chronic inflammatory conditions. Our focus is to develop and advance best in class or first in class
therapies by understanding the pathophysiology and researching novel compounds. Our ultimate goal is to minimize the
burden of disease for patients by addressing unmet needs.
Using PAD(TM) Technology we are introducing a new standard of topical treatment experience for the benefit of patients,
physicians, payers and societies. Our innovative pipeline is comprised of drug candidates within uremic pruritus,
lichen sclerosis, Sjogren's syndrome dry eye, ocular rosacea and atopic dermatitis.
For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com
The above information contains forward-looking statements that provide our expectations or forecasts of future events.
This can be such as the impact of the global COVID-19 pandemic on our business, new product introductions, clinical
development activities and anticipated results, product approvals, financial performance. Terms used may be "aspire",
"believes," "potential," "proposed," "continue," "designed," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words or expressions referencing future events, conditions or circumstances
that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking
statements are subject to risks and uncertainties. This may cause actual results to differ materially from expectations
and it may cause any or all our forward-looking statements here or in other publications to be wrong. Factors that may
affect future results include the impact of the global COVID-19 pandemic, interest rate and currency exchange rate
fluctuations, delay or failure of clinical trials and other development activities, production problems, unexpected
contract breaches or terminations.
(+34) 659 614 173
Pablo Divasson del Fraile
(+34) 93 291 30 87
Corporate Communications, Media and Investors
Susanne Andersen Fitch
(+45) 3131 5119
1. Clinical trial IDs: NCT03802344 and NCT03308799 on Clinicaltrials.gov
2. IQVIA MIDAS(R)
3. Chandran, V., and S.P. Raychaudhuri. 2010. 'Geoepidemiology and environmental factors of psoriasis and psoriatic
arthritis', J. Autoimmune, 34: J314-J21
4. Schafer, T. 2006. 'Epidemiology of psoriasis. Review and the German perspective', Dermatology, 212: 327-37
5. WHO Global report on Psoriasis 2016
2021-02-17 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
(MORE TO FOLLOW) Dow Jones Newswires
February 17, 2021 03:02 ET (08:02 GMT)